MedTrace Logo

Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)

NCT02868060 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-04-29

No results posted yet for this study

Summary

The objective of evaluating the pharmacokinetics and pharmacodynamics of romiplostim in patients with immune thrombocytopenia.

Conditions

  • Immune Thrombocytopenia (ITP)

Interventions

DRUG

Romiplostim

Sponsors & Collaborators

  • Kyowa Kirin China Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Chinese academy of medical science hematology hospital · Chinese academy of medical science hematology hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02868060 on ClinicalTrials.gov